Generics & Biosimilars | Association for Accessible Medicines
AAM All Access Podcast - Featuring AAM CEO Dan Leonard and Apotex President and CEO Jeff Watson
  • Janet Woodcock, M.D. Acting Commissioner, FDA
    FDA Acting Commissioner to Speak at GRx+Biosims
    Dr. Janet Woodcock will bring invaluable insights on generics and biosimilars during this public health emergency. Sign up for GRx+Biosims 2021 now and enjoy $300 in savings.
  • GRx+Biosims 2021: Generics & Biosimilars Conference — Progress + Process
    GRx+Biosims 2021
    Hear the latest from top-in-their-field speakers and government officials, connect with peers from around the world and explore new learning tracks in the generics and biosimilars industry. November 8-10, 2021. Sign up for GRx+Biosims 2021 now and enjoy $300 in savings!
    Watch Video
  • AAM All Access Podcast
    AAM All Access Podcast: Dan Leonard and Jeff Watson
    Dan Leonard speaks with Apotex President and CEO Jeff Watson on the history and vision of the manufacturer and a future of “tremendous opportunity” for generics.
  • ""
    Industry Response to COVID-19
    The coronavirus (COVID-19) pandemic is disrupting everyday life around the world and imposing unprecedented stress on our health care system. Here are some responses and resources from the U.S. generics and biosimilars industry.
  • AAM Report: New Generics Are Less Available in Medicare Than Commercial Plans
    New Generics Are Less Available in Medicare Than Commercial Plans
    AAM releases a new report confirming Medicare Part D plans continue to fail to get new generics to patients.
  • RxFacts
    What We Know—and What We Don’t
    In the past two decades, misunderstood and exaggerated stats regarding the generics supply chain have been cited.
  • Take with Confidence
    Take With Confidence
    Generic Prescription Drugs: Your Health. Our Commitment.
  • AAM Patient Report: Voices of Access
    Patient Stories: Voices of Access
    AAM's Voices of Access report features patients across the country who tell the impact of accessible generic and biosimilar medicines.
  • Interactive Savings Map 2020
    Health Care Savings, State by State
    The average state saved $6.1 billion from the use of generic drugs in 2019. How much did your state save?

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.